DOCSLIB.ORG

WO 2017/161387 Al 21 September 2017 (21.09.2017) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2017/161387 Al 21 September 2017 (21.09.2017) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/161387 Al 21 September 2017 (21.09.2017) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 36/00 (2006.01) A61P 3/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, A61K 36/324 (2006.01) A61P 33/02 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, A61K 36/752 (2006.01) C12N 5/00 (2006.01) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, A61K 47/08 (2006.01) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (21) International Application Number: TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, PCT/US20 17/033234 ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 18 May 2017 (18.05.2017) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (26) Publication Language: English TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (30) Priority Data: DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/390,081 18 March 2016 (18.03.2016) LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 62/390,438 29 March 2016 (29.03.2016) SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventor; and (71) Applicant : RED), Christopher, Brian [US/US]; 880 N. Published: Alameda Street, Apt. 312, Los Angeles, CA 90012 (US). — with international search report (Art. 21(3)) (72) Inventor: COLLINS, Que, T.; 2901 Wilshire Blvd., Suite — before the expiration of the time limit for amending the #206, Santa Monica, CA 90403 (US). claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, — with information concerning request for restoration of the AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, right of priority in respect of one or more priority claims BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (Rules 26bis.3 and 48.2(b)(vii)) (54) Title: COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES (57) Abstract: Synthetic drug development is slow and costly, often running into the billions of dollars. While the benefits of various abundant r and inexpensive natural products, including nat ural oils and extracts, have been postulated and speculated upon for centuries, there has been very little success in achieving national approval (e.g. FDA approval) of natural compounds so that they can be used to benefit animals and patients. As many natural products are often complex and het erogenous, appropriate technologies for rapidly and efficiently predicting efficacy and toxicity of such natural compounds has been sorely lacking. Thus, there has been a long held and still unmet need to determine and teach appropriate health, veterinary, and medical uses for an orange, frankincense and cannabis products in a costef- fective and efficient manner. Accordingly, the present invention teaches compositions, manufac 00 ture, products, and methods of use, prevention and treatment using at least one extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least Fig. 1 one substance or compound isolated from said at least one oil or extract (e.g. a cannabinoid, ses o quiterpene, monoterpene, an ester, ether, alde hyde, phenylpropene, alcohol, ketone, phenol, etc.), so as to benefit medicine, human health and veterinary care. For example, the present invention teaches, the use of at least one extract selected from the group comprising orange, frankincense, cannabis or other o natural oil or extract or at least one substance or compound isolated from said at least one oil or extract to reduce miR21 expression and thus treat/prevent cancer and psoriasis. Compositions of natural extracts and use thereof in methods for preventing or treating diseases CROSS REFERENCE TO RELATED APPLICATION This application claims priority to U.S. Provisional Patent Application No. 62/390,081, filed March 18, 2016, and U.S. Provisional Patent Application No. 62/390,438, filed June 10, 2016 March 29, 2016, the disclosures of which are hereby incorporated by reference in their entirety for all purposes. FIELD OF THE INVENTION The invention relates to compositions and methods for treating or preventing diseases using natural extracts, their derivatives, or their components. BACKGROUND OF THE INVENTION In industrialized countries, cancer and metabolic diseases represent major causes of morbidity and mortality. Recent studies have demonstrated numerous molecular targets for the prevention and/or treatment of cancer and psoriasis. One such target is microRNA-21 (miR21). As most of the targets of miR-21 are tumor suppressors, miR-21 is associated with a wide variety of cancers including that of breast, ovaries, cervix, colon, lung, liver, brain, esophagus, prostate, pancreas, and thyroid. Also in a genome-wide screen, it was found deregulation of microRNA expression in psoriasis skin. miR-21 is one of the microRNAs significantly up-regulated in psoriasis skin lesions. A 2014 meta-analysis of 36 studies evaluated circulating miR-21 as a biomarker of various carcinomas, finding it has potential as a tool for early diagnosis. miR-21 is one of the most frequently upregulated miRNAs in solid tumours, and its high levels were first described in B cell lymphomas. Overall, miR-21 is considered to be a typical Onco-miR, which acts by inhibiting the expression of phosphatases, which limit the activity of signalling pathways such as AKT and MAPK. miR-21 can be transcriptionally activated by NF-κΒ and downregulate phosphatases PDCD4 and PTEN. From the prior art it is known synthetic drugs for treatment of a diseases associated with miR-21 expression. But synthetic drug development is slow and costly, often running into the billions of dollars. While the benefits of various abundant and inexpensive natural products, including natural oils and extracts, have been postulated and speculated upon for centuries, there has been very little success in achieving national approval (e.g. FDA approval) of natural compounds so that they can be used to benefit animals and patients. As many natural products are often complex and heterogenous, appropriate technologies for rapidly and efficiently predicting efficacy and toxicity of such natural compounds has been sorely lacking. Thus, there has been a long held and still unmet need to apply advanced and costly methods, such as gene array, to determine such efficacy and toxicity and teach appropriate health, veterinary, and medical uses for an orange, frankincense, cannabis, etc. products in a cost effective and efficient manner. SUMMARY OF THE INVENTION Virtually all patients could benefit from novel, efficacious drug compositions. The present invention provides novel orange, frankincense, cannabis and other natural oil and extract related compositions and inexpensive drug compositions for preventing and/or treating various conditions, diseases, and maladies especially metabolic diseases and disorders, cancer, psoriasis and improving health and well-being in general. The present invention also provides corresponding methods for producing such compositions and methods of preventing a condition, disorder or disease and treating a condition, disorder or disease in an animal or human, wherein the compositions, manufacture, or products of the present invention are provided to said animal or human. In a first aspect, according to the present invention, the problem of the prior art is solved by a composition for reducing miR-21 expression in a cell or tissue of a subject comprising deuterium depleted water (DDW) and/or at least one oil or extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least one substance or compound isolated from said at least one oil or extract. The composition may further comprise at least one carrier and/or at least one excipient, wherein said composition is used for treatment of a disease associated with miR-21 expression. In a second aspect, this invention relates to a method for reducing mir-21 and other oncogene expression in a cell or tissue of a subject comprising administering to the subject a composition comprising deuterium depleted water (DDW) and/or at least one oil or extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least one substance or compound isolated from said at least one oil or extract. The composition may further comprise at least one carrier and/or at least one excipient, wherein the method is for treatment of a disease associated with mir-21 and/or other oncogene expression. The method of suppressing miR21 can be seen as a method of treating and/or preventing cancer, psoriasis, and or any other disease associated with miR-21 and/or other oncogene expression. The method may be accomplished by administering to the subject an appropriate amount of composition comprising deuterium depleted water (DDW) and/or at least one oil or extract selected from the group comprising orange, frankincense, cannabis or other natural oil or extract or at least one substance or compound isolated from said at least one oil or extract, which showing potent miR21 suppression in vitro and in vivo or at least one substance or compound with miR21 suppressive activity that are isolated from such extracts.
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • The Rise and Fall of the Bovine Corpus Luteum
    University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-6-2017 The Rise and Fall of the Bovine Corpus Luteum Heather Talbott University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, Molecular Biology Commons, and the Obstetrics and Gynecology Commons Recommended Citation Talbott, Heather, "The Rise and Fall of the Bovine Corpus Luteum" (2017). Theses & Dissertations. 207. https://digitalcommons.unmc.edu/etd/207 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM by Heather Talbott A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor John S. Davis University of Nebraska Medical Center Omaha, Nebraska May, 2017 Supervisory Committee: Carol A. Casey, Ph.D. Andrea S. Cupp, Ph.D. Parmender P. Mehta, Ph.D. Justin L. Mott, Ph.D. i ACKNOWLEDGEMENTS This dissertation was supported by the Agriculture and Food Research Initiative from the USDA National Institute of Food and Agriculture (NIFA) Pre-doctoral award; University of Nebraska Medical Center Graduate Student Assistantship; University of Nebraska Medical Center Exceptional Incoming Graduate Student Award; the VA Nebraska-Western Iowa Health Care System Department of Veterans Affairs; and The Olson Center for Women’s Health, Department of Obstetrics and Gynecology, Nebraska Medical Center.
    [Show full text]
  • Cannabinoid CB1R Receptor Mediates Metabolic Syndrome in Models of Circadian and Glucocorticoid Dysregulation Nicole Bowles
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2013 Cannabinoid CB1R Receptor Mediates Metabolic Syndrome in Models of Circadian and Glucocorticoid Dysregulation Nicole Bowles Follow this and additional works at: http://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons Recommended Citation Bowles, Nicole, "Cannabinoid CB1R Receptor Mediates Metabolic Syndrome in Models of Circadian and Glucocorticoid Dysregulation" (2013). Student Theses and Dissertations. Paper 232. This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact [email protected]. CANNABINOID CB1R RECEPTOR MEDIATES METABOLIC SYNDROME IN MODELS OF CIRCADIAN AND GLUCOCORTICOID DYSREGULATION A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Nicole Bowles June 2013 Copyright by Nicole Bowles 2013 CANNABINOID CB1R RECEPTOR MEDIATES METABOLIC SYNDROME IN MODELS OF CIRCADIAN AND GLUCOCORTICOID DYSREGULATION Nicole Bowles, Ph.D. The Rockefeller University 2013 The most recent projections in the growing obesity rates across the nation show an increase to 60% by the year 2030. These growing rates of obesity are paralleled by an increased rates of depressive conditions, anxiety, and sleep loss, often with environmental factors at the root of the cause. Stress and the stress response is a dynamic system that reflects one’s ability to cope with events, behaviorally or physiologically, as stressors occur over a lifetime. While many key players mediate the effects of stress exposure on disease outcomes including the sympathetic nervous system, parasympathetic, inflammatory cytokines and metabolic hormones, this dissertation focuses on glucocorticoids because of the extensive regulatory role they play in mounting the adaptative response to stress.
    [Show full text]
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • Caractérisation De La Polarisation Des Macrophages Pulmonaires Humains Et Voies De Régulation Charlotte Abrial
    Caractérisation de la polarisation des macrophages pulmonaires humains et voies de régulation Charlotte Abrial To cite this version: Charlotte Abrial. Caractérisation de la polarisation des macrophages pulmonaires humains et voies de régulation. Biologie cellulaire. Université de Versailles-Saint Quentin en Yvelines, 2014. Français. NNT : 2014VERS0033. tel-01326578 HAL Id: tel-01326578 https://tel.archives-ouvertes.fr/tel-01326578 Submitted on 8 Dec 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université de Versailles Saint Quentin en Yvelines UFR DES SCIENCES DE LA SANTÉ École doctorale GAO "Des génomes aux organismes" Année universitaire 2014 – 2015 N° le 03 novembre 2014 THESE DE DOCTORAT Présentée pour l’obtention du grade de DOCTEUR DE L’UNIVERSITÉ VERSAILLES – SAINT QUENTIN EN YVELINES Spécialité : Biologie cellulaire Par Charlotte ABRIAL Caractérisation de la polarisation des macrophages pulmonaires humains et voies de régulation Composition du jury: Directeur de thèse Pr. DEVILLIER Philippe Rapporteur Dr. FROSSARD Nelly Rapporteur Pr. LAGENTE Vincent Examinateur Dr. TOUQUI Lhousseine Université de Versailles Saint Quentin en Yvelines UFR DES SCIENCES DE LA SANTÉ École doctorale GAO "Des génomes aux organismes" Année universitaire 2014 – 2015 N° THESE DE DOCTORAT Présentée pour l’obtention du grade de DOCTEUR DE L’UNIVERSITÉ VERSAILLES – SAINT QUENTIN EN YVELINES Spécialité : Biologie cellulaire Par Charlotte ABRIAL Caractérisation de la polarisation des macrophages pulmonaires humains et voies de régulation Composition du jury: Directeur de thèse Pr.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Deutsche Gesellschaft Für Experimentelle Und Klinische Pharmakologie Und Toxikologie E.V
    Naunyn-Schmiedeberg´s Arch Pharmacol (2013 ) 386 (Suppl 1):S1–S104 D OI 10.1007/s00210-013-0832-9 Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie e.V. Abstracts of the 79 th Annual Meeting March 5 – 7, 2013 Halle/Saale, Germany This supplement was not sponsored by outside commercial interests. It was funded entirely by the publisher. 123 S2 S3 001 003 Multitarget approach in the treatment of gastroesophagel reflux disease – Nucleoside Diphosphate Kinase B is a Novel Receptor-independent Activator of comparison of a proton-pump inhibitor with STW 5 G-protein Signaling in Clinical and Experimental Atrial Fibrillation Abdel-Aziz H.1,2, Khayyal M. T.3, Kelber O.2, Weiser D.2, Ulrich-Merzenich G.4 Abu-Taha I.1, Voigt N.1, Nattel S.2, Wieland T.3, Dobrev D.1 1Inst. of Pharmaceutical & Medicinal Chemistry, University of Münster Pharmacology, 1Universität Duisburg-Essen Institut für Pharmakologie, Hufelandstr. 55, 45122 Essen, Hittorfstr 58-62, 48149 Münster, Germany Germany 2Steigerwald Arzneimittelwerk Wissenschaft, Havelstr 5, 64295 Darmstadt, Germany 2McGill University Montreal Heart Institute, 3655 Promenade Sir-William-Osler, Montréal 3Faculty of Pharmacy, Cairo University Pharmacology, Cairo Egypt Québec H3G 1Y6, Canada 4Medizinische Poliklinik, University of Bonn, Wilhelmstr. 35-37, 53111 Bonn, Germany 3Medizinische Fakultät Mannheim der Universität Heidelberg Institutes für Experimentelle und Klinische Pharmakologie und Toxikologie, Maybachstr. 14, 68169 Gastroesophageal reflux disease (GERD) was the most common GI-diagnosis (8.9 Mannheim, Germany million visits) in the US in 2012 (1). Proton pump inhibitors (PPI) are presently the mainstay of therapy, but in up to 40% of the patients complete symptom control fails.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Clinical Policy: Mecasermin (Increlex) Reference Number: ERX.SPA.209 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log
    Clinical Policy: Mecasermin (Increlex) Reference Number: ERX.SPA.209 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Mecasermin (Increlex®) is an insulin growth factor-1 (IGF-1) analogue. FDA Approved Indication(s) Increlex is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Limitation(s) of use: Increlex is not a substitute to GH for approved GH indications. Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Increlex is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Severe Primary IGF-1 Deficiency (must meet all): 1. Diagnosis of IGF-1 deficiency growth failure and associated growth failure with one of the following (a or b): a. Severe primary IGF-1 deficiency as defined by all (i through iii): i. Height standard deviation score (SDS) ≤ –3.0; ii. Basal IGF-1 SDS ≤ –3.0; iii. Normal or elevated GH level; b. GH gene deletion with development of neutralizing antibodies to GH; 2. Prescribed by or in consultation with an endocrinologist; 3. Age ≥ 2 and <18 years; 4. At the time of request, member does not have closed epiphyses; 5. Dose does not exceed 0.12 mg/kg twice daily.
    [Show full text]
  • Functional Characterization of Prenyltransferases Involved in the Biosynthesis of Polycyclic Polyprenylated Acylphloroglucinols in the Genus Hypericum
    Functional characterization of prenyltransferases involved in the biosynthesis of polycyclic polyprenylated acylphloroglucinols in the genus Hypericum Von der Fakultät für Lebenswissenschaften der Technischen Universität Carolo-Wilhelmina zu Braunschweig zur Erlangung des Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigte D i s s e r t a t i o n von Mohamed Mamdouh Sayed Nagia aus Kalyobiya/ Ägypten 1. Referent: Professor Dr. Ludger Beerhues 2. Referent: Professor Dr. Alain Tissier eingereicht am: 30.07.2018 mündliche Prüfung (Disputation) am: 15.10.2018 Druckjahr 2018 „Gedruckt mit Unterstützung des Deutschen Akademischen Austauschdienstes“ „Und sag: O mein Herr, mehre mein Wissen“ Der Edle Qur’an [20: 114] Vorveröffentlichungen der Dissertation Teilergebnisse aus dieser Arbeit wurden mit Genehmigung der Fakultät für Lebenswissenschaften, vertreten durch den Mentor der Arbeit, in folgenden Beiträgen vorab veröffentlicht: Publikationen Nagia, M., Gaid, M., Biedermann, E., Fiesel, T., El-Awaad, I., Haensch, R., Wittstock, U., and Beerhues, L. Sequential regiospecific gem-diprenylation of tetrahydroxyxanthone by prenyltransferases from Hypericum sp. (Submitted). Nagia, M., Gaid, M., Beuerle, T., and Beerhues, L. Successive xanthone prenylation in Hypericum sampsonii. Planta Medica International Open 4, Tu-SL-01 (2017). doi: 10.1055/s-0037-1608308 Tagungsbeiträge A. Vorträge Nagia M., Gaid M., Biedermann E., Beuerle T., Beerhues L., Successive xanthone prenylation in Hypericum sampsonii, 65th Annual Meeting of the Society for Medicinal Plant and Natural Product Research, Basel, Switzerland, 3. – 7. September 2017. Nagia M., Gaid M., Behrends S., Beerhues L., Novel PPAP-related prenyltransferases, 4. SynFoBiA -Kolloquium des Pharmaverfahrenstechnik (PVZ), Braunschweig, Germany, 26. February 2016. Nagia M., Gaid M., Beurele T., Biedermann E., Beerhues L., Aromatic Prenyltransferases from Hypericum sampsonii, Postgraduate workshop of the section „Natural Products“ German Society for Plant Sciences (DBG), Meisdorf, Germany , 11.
    [Show full text]